Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.

scientific article published on 13 May 2016

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1002976737
P356DOI10.1038/MODPATHOL.2016.88
P932PMC publication ID4967011
P698PubMed publication ID27174589

P50authorJeremy A. SquireQ39802515
Tamara L LotanQ62091289
Peter S NelsonQ100440151
Lawrence D TrueQ114402092
P2093author name stringLadan Fazli
Martin Gleave
Dean Troyer
Ian M Thompson
Wei Wei
Daniel W Lin
Ziding Feng
Peter R Carroll
James D Brooks
Jesse K McKenney
Jeffrey Simko
Raymond Lance
Antonio Hurtado-Coll
Sarah T Hawley
Olga Ludkovski
Carlos L Morais
Tamara Jamaspishvili
Karen Lopez
Liana B Guedes
P2860cites workExome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerQ24616117
The genomic complexity of primary human prostate cancerQ24617949
A coding-independent function of gene and pseudogene mRNAs regulates tumour biologyQ24632651
Methodological aspects of the molecular and histological study of prostate cancer: focus on PTENQ27005677
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.Q27851411
Integrative clinical genomics of advanced prostate cancerQ27853170
The mutational landscape of lethal castration-resistant prostate cancerQ29614634
Integrative genomic profiling of human prostate cancerQ29619905
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerQ33723651
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformationQ34109986
Genetic markers associated with early cancer-specific mortality following prostatectomyQ34340799
Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancerQ35234584
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Q35540013
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomyQ36610246
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate CancerQ36887707
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.Q36959119
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progressionQ37383459
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue MicroarrayQ38066715
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneityQ38400993
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patientsQ38738670
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerQ39401816
A robust immunohistochemical assay for detecting PTEN expression in human tumorsQ39646962
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasiasQ40293372
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancerQ40978920
Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusionQ42119481
PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomyQ43089446
Is PTEN loss associated with clinical outcome measures in human prostate cancer?Q43249619
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancerQ45251986
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancerQ47919199
TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.Q51837762
Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate CancerQ57782669
Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancerQ57790298
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplicationsQ57790325
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcomeQ57790493
ThePTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletionQ63966367
Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancerQ87745893
P433issue8
P921main subjectprostate cancerQ181257
immunohistochemistryQ899285
P304page(s)904-914
P577publication date2016-05-13
P1433published inModern PathologyQ15724578
P1476titleAnalytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
P478volume29

Reverse relations

cites work (P2860)
Q36407003Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.
Q49964150Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer
Q49818398Clinical implications of PTEN loss in prostate cancer
Q47129857Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer
Q54964875Emerging biomarkers in the diagnosis of prostate cancer.
Q93196102Emerging role of PTEN loss in evasion of the immune response to tumours
Q90706115Everolimus inhibits the proliferation and migration of epidermal growth factor receptor-resistant lung cancer cells A549 via regulating the microRNA-4328/phosphatase and tensin homolog signaling pathway
Q98945179High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts
Q36192598MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study
Q50133991Molecular Biomarkers in the Clinical Management of Prostate Cancer
Q47877197PTEN allelic loss is an important mechanism in the late stage of development of oral leucoplakia into oral squamous cell carcinoma
Q42371556PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort
Q57049913PTEN status assessment in the Johns Hopkins active surveillance cohort
Q64114534Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology
Q90029848Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
Q38967389Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers
Q51586225TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Q90029873The Challenges of Optimizing Biomarkers To Guide Clinical Decision Making
Q48228320Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
Q48231392Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections
Q47908752Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
Q47231171p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer

Search more.